Manages incomplete or inevitable abortion. ANDA 200219, held by Hikma Farmacêutica. Oxytocin.
As of Nov 22, 2026, ANDA 200219 (Oxytocin), held by Hikma Farmacêutica, was first approved by FDA on Feb 13, 2013, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE IMPORTANT NOTICE Oxytocin Injection, USP (synthetic) is indicated for the medical rather than the elective induction of labor. Available data and information are inadequate to define the benefits to risks considerations in the use of the drug product for elective induction. Elective induction of labor is defined as the initiation of labor for convenience in an individual with a term pregnancy who is free of medical indications. Antepartum Oxytocin Injection, USP (synthetic) is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable, in order to achieve early vaginal delivery for fetal or maternal reasons.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 13, 2013 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Oxytocin10USP UNITS/ML (10USP UNITS/ML) · injectable;injection | Oxytocin | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters